Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.